Gracia J M, Jimenez A
Cancer Chemother Pharmacol. 1982;7(2-3):199-201. doi: 10.1007/BF00254548.
Twenty-four evaluable patients with small cell carcinoma of the lung were treated with an escalating chemotherapy regimen including Cyclophosphamide, Adriamycin, Vincristine and VP16-213. The initial doses were CTX 800 mg/m2 i.v. day 1; ADR 50 mg/m2 i.v. day 1; VCR 1.4 mg/m2 day 1 weekly; and VP16-213 100 mg/m1 i.v. days 14-18 every 4 weeks, CTX and ADR were escalated by 100 and 10 mg/m2 respectively in each subsequent cycle according to blood count. Hematologic toxicity was minimal and the treatment was well tolerated. Partial responses and complete responses were 9 of 19 and 5 of 19 respectively for patients with limited disease, and 4 of 5 respectively for patients with extensive disease. The overall response rate for the whole group was 79% These results must be considered preliminary.
24例可评估的小细胞肺癌患者接受了一种递增化疗方案，该方案包括环磷酰胺、阿霉素、长春新碱和依托泊苷（VP16-213）。初始剂量为：环磷酰胺800mg/m²，静脉注射，第1天；阿霉素50mg/m²，静脉注射，第1天；长春新碱1.4mg/m²，第1天，每周一次；依托泊苷100mg/m²，静脉注射，第14 - 18天，每4周一次。在随后的每个周期中，根据血细胞计数，环磷酰胺和阿霉素分别递增100mg/m²和10mg/m²。血液学毒性最小，治疗耐受性良好。局限期患者部分缓解和完全缓解分别为19例中的9例和5例，广泛期患者分别为5例中的4例。全组总缓解率为79%。这些结果必须视为初步结果。
